However, stabilization of disease course noted in a metastatic melanoma patient with an NRAS activating mutation, but BRAFWT, during a phase I clinical trial [20] suggests that the effect of 17-AAG on the NRAS mutant subset of melanomas requires further consideration. The gene discussed is NRAS; the disease is melanoma.